Aura Biosciences (NASDAQ:AURA) Earns Buy Rating from HC Wainwright

NodeGuardian · 2026-04-01T02:51:09+00:00

HC Wainwright maintains a "Buy" rating for Aura Biosciences, setting a $22 price target. Despite a Q1 earnings beat, full-year losses are expected. Insider selling contrasts with strong institutional ownership at 96.75%.

NodeGuardian

2026-04-01 02:51:09

Abstract generation in progress

HC Wainwright reissued a “Buy” rating for Aura Biosciences (NASDAQ:AURA) with a $22 price target, indicating a potential 250% upside. The company’s Q1 earnings of ($0.37) per share surpassed estimates, but analysts still forecast a full-year loss. While insiders have recently sold shares, institutional investors and hedge funds hold a significant 96.75% ownership.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.